1. Home
  2. AGPU vs PMVP Comparison

AGPU vs PMVP Comparison

Compare AGPU & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axe Compute Inc. Common Stock

AGPU

Axe Compute Inc. Common Stock

N/A

Current Price

$11.52

Market Cap

83.5M

Sector

N/A

ML Signal

N/A

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

N/A

Current Price

$1.75

Market Cap

71.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AGPU
PMVP
Founded
2002
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
71.1M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
AGPU
PMVP
Price
$11.52
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.20
AVG Volume (30 Days)
299.0K
★ 515.8K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $125,284.00
N/A
Revenue This Year
$48,110.47
N/A
Revenue Next Year
$614.07
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$1.02
52 Week High
$13.49
$1.88

Technical Indicators

Market Signals
Indicator
AGPU
PMVP
Relative Strength Index (RSI) 53.34 68.53
Support Level $7.00 $1.05
Resistance Level $13.48 $1.88
Average True Range (ATR) 0.98 0.11
MACD -0.10 0.02
Stochastic Oscillator 33.56 89.89

Price Performance

Historical Comparison
AGPU
PMVP

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: